ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Yang CHEN, Lu-Ying GUO, Ling-Fei ZHAO, Yan-Hong MA, Xue-Ling ZHU, Ying XU, Jiang-Hua CHEN. Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?. J Geriatr Cardiol 2020; 17(12): 782-786. doi: 10.11909/j.issn.1671-5411.2020.12.002
Citation: Yang CHEN, Lu-Ying GUO, Ling-Fei ZHAO, Yan-Hong MA, Xue-Ling ZHU, Ying XU, Jiang-Hua CHEN. Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?. J Geriatr Cardiol 2020; 17(12): 782-786. doi: 10.11909/j.issn.1671-5411.2020.12.002

Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?

doi: 10.11909/j.issn.1671-5411.2020.12.002
More Information
  • loading
  • [1]
    Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081. doi: 10.1016/S0140-6736(10)60674-5
    [2]
    Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169. doi: 10.1161/01.CIR.0000095676.90936.80
    [3]
    Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339-352. doi: 10.1016/S0140-6736(13)60595-4
    [4]
    Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753. http://www.ncbi.nlm.nih.gov/pubmed/11856780
    [5]
    Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697. doi: 10.1056/NEJMra000050
    [6]
    Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 2013; 34: 886-893c. doi: 10.1093/eurheartj/ehs262
    [7]
    Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. doi: 10.1056/NEJM199108013250501
    [8]
    Cohn JN, Tognoni G. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. doi: 10.1056/NEJMoa010713
    [9]
    Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017; 3: 7-11. doi: 10.15420/cfr.2016:25:2
    [10]
    McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004. doi: 10.1056/NEJMoa1409077
    [11]
    Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/ HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137-e161.
    [12]
    Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21: 1169-1186. doi: 10.1002/ejhf.1531
    [13]
    Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018; 6: 489-498. doi: 10.1016/j.jchf.2018.02.004
    [14]
    Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med 2016; 375: 1868-1877.
    [15]
    Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395. doi: 10.1016/S0140-6736(12)61227-6
    [16]
    Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2015; 17: 510-517. doi: 10.1002/ejhf.232
    [17]
    van de Bovenkamp AA, van Rossum AC, Handoko ML. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2020; 382: 1180-1183. doi: 10.1056/NEJMc2000284
    [18]
    Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 2020; 142: 1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643
    [19]
    Wachter R, Shah SJ, Cowie MR, et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Fail 2020; 7: 856-864. doi: 10.1002/ehf2.12694
    [20]
    Shah SJ, Wachter R, Solomon S, et al. Angiotensin receptor neprilysin inhibition compared with individualized medical therapy for comorbidities in patients with heart failure and preserved ejection fraction-the PARALLAX trial. Presented at the ESC Congress, Amsterdam, The Netherlands, 2020.
    [21]
    Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin- neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380: 539-548. doi: 10.1056/NEJMoa1812851
    [22]
    Jing W, Vaziri ND, Nunes A, et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Transl Res 2017; 9: 5473-5484.
    [23]
    Mohany M, Alanazi AZ, Alqahtani F, et al. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats. PeerJ 2020; 8: e9196. doi: 10.7717/peerj.9196
    [24]
    Sabbah HN, Zhang K, Gupta RC, et al. Effects of angiotensin- neprilysin inhibition in canines with experimentally induced cardiorenal syndrome. J Card Fail 2020; 26: 987-997. doi: 10.1016/j.cardfail.2020.08.009
    [25]
    Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril/ valsartan versus irbesartan in patients with chronic kidney disease. Circulation 2018; 138: 1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818
    [26]
    Coronel F, Cigarrán S, García-Mena M, et al. Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI. Nefrologia 2008; 28: 56-60. http://europepmc.org/abstract/MED/18336132
    [27]
    Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878. doi: 10.1056/NEJMoa011489
    [28]
    Croom KF, Curran MP, Goa KL, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999-1028. doi: 10.2165/00003495-200464090-00011
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (82) PDF downloads(16) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return